AIDOT (CEO Jeong Jae-hoon) has launched “Cerviray,” a machine-learning-based AI solution for cervical cancer.

Cervical cancer testing is primarily conducted through cytology. Cerviray is an AI software-based diagnostic support system that assists with primary (first-pass) cervical interpretation. Cerviray AI provides a service in which the cervix is magnified and the AI performs an initial assessment of its condition. Compared with interpretation performed by medical staff alone, it reduces reading time and offers higher accuracy. The current interpretation accuracy of Cerviray AI reaches 93%.

The Cerviray product was commercialized this year. In October, it placed first at the “2020 Northeast Asia Innovation Forum and Project IR Roadshow” held in China. It received high marks for aligning with Chinese government initiatives related to women’s health and for presenting a new approach in place of conventional cervical cancer pre-diagnosis methods centered on cytology.

AIDOT entered China by establishing a joint venture company there. It is currently conducting sales efforts targeting approximately 11,000 women’s hospitals in China and has successfully signed contracts with many hospitals.

After being selected for SW High-Growth Club 200, AIDOT achieved 100% of its targeted revenue and employment performance goals for the year.

It recorded approximately KRW 1 billion in revenue this year and hired four new employees. In addition to pursuing domestic and international certifications, the company carried out active marketing efforts alongside commercialization of the product. Beyond China, it has been discussing exports and cooperation with more than 40 companies across 16 countries in the second half of this year alone, including Vietnam and Indonesia. In addition to cervical cancer, it is continuously developing carotid ultrasound AI, AI for predicting cerebral aneurysm rupture, and real-time endoscopy AI, among other technologies.

The company expects the new year to be a year of full-scale expansion. It anticipates securing more than KRW 3 billion in revenue in the first half of the new year alone. It plans to expand the organization and strengthen its operational structure by recruiting strong practical talent for areas including AI development and global exports, while also focusing on exports by reinforcing global marketing.

An AIDOT official said, “Even amid the COVID-19 situation, we focused on promoting the product by actively participating in online exhibitions such as GMES, Bio Health Worldwide, and Russia Open Innovation,” adding, “In the new year, we will contribute to enhancing the nation’s standing by distributing outstanding AI medical SW to the world.”

Published: December 27, 2020 / ETNews / Reporter Kim Ji-seon